RxDoctor Payments Data

Deborah Hung, MD

Infectious Disease · Boston, MANPI 1629068267

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $124,000 of the $130,221 with a category attached, or 95.2%. Genentech, Inc. accounts for 70.1% of it on its own, with 2 other manufacturers making up the rest. Among infectious disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$130,221in general payments, 2019–2025

Across 16 payments — averaging $8138.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$91K
  • Genentech USA, Inc.$38K
  • Vertex$1K

What the payments were for

  • Consulting fees$124,00095%
  • Speaking & faculty fees$1,0801%
  • Travel & lodging$5,0274%
  • Food & beverage$1140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.11$91,258
Genentech USA, Inc.4$37,883
Vertex1$1,080

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$130,221 in reported general payments places this provider in the 95th percentile of 368 infectious disease providers in Massachusetts.

See all infectious disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$10,739
Medicare patients
24
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →